title: Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases".
authors: Division of Rheumatology, University of Nevada School of Medicine, Reno, USA, jpixley@medicine.nevada.edu.
authors: John
authors: J
authors: Pixley
mesh_terms: D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012216:Rheumatic Diseases / Q000097:blood* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha
references: J Rheumatol Suppl. 2010 May;85:40-52
references: 20436164
references: Ann Rheum Dis. 2012 Jan;71(1):38-44
references: 21917824
references: N Engl J Med. 2003 Feb 13;348(7):601-8
references: 12584368
references: Ann Rheum Dis. 2009 Apr;68(4):531-5
references: 18375542
references: Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34
references: 23532441
references: J Rheumatol. 2007 Dec;34(12):2365-73
references: 18050376